Cardiovascular Pharmacogenomics: The Future of Cardiovascular Therapeutics?

Canadian Journal of Cardiology

Volumn 29, Issue 1, 2013, Pages 58-66

  Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADENOSINE DIPHOSPHATE; ALLOPURINOL; AZATHIOPRINE; CARBAMAZEPINE; CARDIOVASCULAR AGENT; CLOPIDOGREL; CODEINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; SIMVASTATIN; TAMOXIFEN; WARFARIN;

ACUTE CORONARY SYNDROME; AMINO ACID SEQUENCE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG METABOLISM; DRUG TRANSPORT; DRUG UPTAKE; GENE DELETION; GENE INSERTION; GENE LOCUS; GENE TRANSFER; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; MYOPATHY; PERSONALIZED MEDICINE; PHARMACOGENOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; PHARMACOGENETICS;

EID: 84871405031     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.07.845     Document Type: Review

References (85)

1. Hulot J.S., Bura A., Villard E., et al. Cytochrome p450 2c19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006, 108:2244-2247.
2. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-362.
3. Simon T., Verstuyft C., Mary-Krause M., et al. Genetic determinants of response to clopidogrel and cardiovascular events. New Engl J Med 2009, 360:363-375.
4. Collet J.P., Hulot J.S., Pena A., et al. Cytochrome p450 2c19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009, 373:309-317.
5. French B., Joo J., Geller N.L., et al. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 2010, 11:108.
6. Klein T.E., Altman R.B., et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. New Engl J Med 2009, 360:753-764. International Warfarin Pharmacogenetics Consortium.
7. Huang S.M., Zhang L., Giacomini K.M. The international transporter consortium: a collaborative group of scientists from academia, industry, and the FDA. Clin Pharmacol Ther 2010, 87:32-36.
8. Pirmohamed M., Aithal G.P., Behr E., Daly A., Roden D. The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. Clin Pharmacol Ther 2011, 89:784-785.
9. Mega J.L., Simon T., Collet J.P., et al. Reduced-function cyp2c19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010, 304:1821-1830.
10. Holmes M.V., Perel P., Shah T., Hingorani A.D., Casas J.P. Cyp2c19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011, 306:2704-2714.
11. Johnson J.A., Roden D.M., Lesko L.J., Ashley E., Klein T.E., Shuldiner A.R. Clopidogrel: a case for indication-specific pharmacogenetics. Clin Pharmacol Ther 2012, 91:774-776.
12. Shuldiner A.R., O'Connell J.R., Bliden K.P., et al. Association of cytochrome p450 2c19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009, 302:849-857.
13. Link E., Parish S., Armitage J., et al. Slco1b1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008, 359:789-799.
14. Kaab S., Darbar D., van Noord C., et al. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J 2009, 30:813-819.
15. Roden D.M., Xu H., Denny J.C., Wilke R.A. Electronic medical records as a tool in clinical pharmacology: opportunities and challenges. Clin Pharmacol Ther 2012, 91:1083-1086.
16. Roden D.M., Pulley J.M., Basford M.A., et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther 2008, 84:362-369.
17. Ioannidis J.P., Ntzani E.E., Trikalinos T.A., Contopoulos-Ioannidis D.G. Replication validity of genetic association studies. Nat Genet 2001, 29:306-309.
18. Hirschhorn J.N., Lohmueller K., Byrne E., Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002, 4:45-61.
19. Klein T.E., Altman R.B., et al. Estimation of a warfarin dose with clinical and pharmacogenetic data. New Engl J Med 2009, 360:753-764. International Warfarin Pharmacogenetics Consortium.
20. Cooper G.M., Johnson J.A., Langaee T.Y., et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008, 112:1022-1027.
21. Takeuchi F., McGinnis R., Bourgeois S., et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009, 5:e1000433.
22. Mallal S., Nolan D., Witt C., et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002, 359:727-732.
23. Mallal S., Phillips E., Carosi G., et al. HLA-B*5701 screening for hypersensitivity to abacavir. New Engl J Med 2008, 358:568-579.
24. Hung S.I., Chung W.H., Jee S.H., et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006, 16:297-306.
25. McCormack M., Alfirevic A., Bourgeois S., et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. New Engl J Med 2011, 364:1134-1143.
26. Chen P., Lin J.J., Lu C.S., et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. New Engl J Med 2011, 364:1126-1133.
27. Daly A.K., Donaldson P.T., Bhatnagar P., et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009, 41:816-819.
28. Sibbing D., Koch W., Gebhard D., et al. Cytochrome 2c19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010, 121:512-518.
29. Rettie A.E., Wienkers L.C., Gonzalez F.J., Trager W.F., Korzekwa K.R. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994, 4:39-42.
30. Aithal G.P., Day C.P., Kesteven P.J., Daly A.K. Association of polymorphisms in the cytochrome p450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999, 353:717-719.
31. Ramirez A.H., Shi Y., Schildcrout J.S., et al. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics 2012, 13:407-418.
32. Sekino K., Kubota T., Okada Y., et al. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 2003, 59:589-592.
33. Hallberg P., Karlsson J., Kurland L., et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens 2002, 20:2089-2093.
34. Meyer U.A., Zanger U.M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997, 37:269-296.
35. Lennard M.S., Silas J.H., Freestone S., Trevethick J. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br J Clin Pharmacol 1982, 14:301-303.
36. Lee J.T., Kroemer H.K., Silberstein D.J., et al. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. New Engl J Med 1990, 322:1764-1768.
37. Llerena A., Berecz R., de la Rubia A., Dorado P. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol 2002, 16:361-364.
38. Ho R.H., Kim R.B. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005, 78:260-277.
39. Giacomini K.M., Huang S.M., Tweedie D.J., et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010, 9:215-236.
40. Hoffmeyer S., Burk O., von Richter O., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with p- glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000, 97:3473-3478.
41. Kimchi-Sarfaty C., Oh J.M., Kim I.W., et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315:525-528.
42. Voora D., Shah S.H., Spasojevic I., et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009, 54:1609-1616.
43. Liggett S.B., Mialet-Perez J., Thaneemit-Chen S., et al. A polymorphism within a conserved {beta}1-adrenergic receptor motif alters cardiac function and {beta}-blocker response in human heart failure. Proc Natl Acad Sci U S A 2006, 103:11288-11293.
44. Parvez B., Chopra N., Rowan S., et al. A common beta1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J Am Coll Cardiol 2012, 59:49-56.
45. Rost S., Fregin A., Ivaskevicius V., et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004, 427:537-541.
46. Rieder M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New Engl J Med 2005, 352:2285-2293.
47. Dang M.T., Hambleton J., Kayser S.R. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 2005, 39:1008-1012.
48. Scott S.A., Edelmann L., Kornreich R., Desnick R.J. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 2008, 82:495-500.
49. Harrington D.J., Gorska R., Wheeler R., et al. Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Haemost 2008, 6:1663-1670.
50. Roden D.M., Viswanathan P.C. Genetics of acquired long QT syndrome. J Clin Invest 2005, 115:2025-2032.
51. Sesti F., Abbott G.W., Wei J., et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 2000, 97:10613-10618.
52. Yang P., Kanki H., Drolet B., et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002, 105:1943-1948.
53. Itoh H., Sakaguchi T., Ding W.G., et al. Latent genetic backgrounds and molecular pathogenesis in drug-induced long QT syndrome. Circ Arrhythm Electrophysiol 2009, 2:511-523.
54. Donger C., Denjoy I., Berthet M., et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997, 96:2778-2781.
55. Paulussen A.D., Gilissen R.A., Armstrong M., et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) 2004, 82:182-188.
56. Napolitano C., Schwartz P.J., Brown A.M., et al. Evidence for a cardiac ion channel mutation underlying drug-induced qt prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000, 11:691-696.
57. Kaab S., Crawford D.C., Sinner M.F., et al. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet 2012, 5:91-99.
58. Manolio T.A. Genomewide association studies and assessment of the risk of disease. New Engl J Med 2010, 363:166-176.
59. Wang J., Klysik E., Sood S., Johnson R.L., Wehrens X.H., Martin J.F. PITX2 prevents susceptibility to atrial arrhythmias by inhibiting left-sided pacemaker specification. Proc Natl Acad Sci U S A 2010, 107:9753-9758.
60. Harismendy O., Notani D., Song X., et al. 9p21 DNA variants associated with coronary artery disease impair interferon-[ggr] signalling response. Nature 2011, 470:264-268.
61. Visel A., Zhu Y., May D., et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature 2010, 464:409-412.
62. Gudbjartsson D.F., Arnar D.O., Helgadottir A., et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007, 448:353-357.
63. Vaglio J., Rowan S., Kucera G., et al. A common single nucleotide polymorphism associated with atrial fibrillation modulates symptomatic response to antiarrhythmic drug therapy (abstract). Circulation 2010, 122:A17900.
64. Husser D., Adams V., Piorkowski C., Hindricks G., Bollmann A. Chromosome 4q25 variants and atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol 2010, 55:747-753.
65. Arking D.E., Pfeufer A., Post W., et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet 2006, 38:644-651.
66. Newton-Cheh C., Eijgelsheim M., Rice K.M., et al. Common variants at ten loci influence QT interval duration in the QTGEN study. Nat Genet 2009, 41:399-406.
67. Pfeufer A., Sanna S., Arking D.E., et al. Common variants at ten loci modulate the QT interval duration in the QTSCD study. Nat Genet 2009, 41:407-414.
68. Kao W.H., Arking D.E., Post W., et al. Genetic variations in nitric oxide synthase 1 adaptor protein are associated with sudden cardiac death in US white community-based populations. Circulation 2009, 119:940-951.
69. Becker M.L., Visser L.E., Newton-Cheh C., et al. A common NOS1AP genetic polymorphism is associated with increased cardiovascular mortality in users of dihydropyridine calcium channel blockers. Br J Clin Pharmacol 2009, 67:61-67.
70. Eijgelsheim M., Newton-Cheh C., Aarnoudse A.L., et al. Genetic variation in NOS1AP is associated with sudden cardiac death: evidence from the Rotterdam study. Hum Mol Genet 2009, 18:4213-4218.
71. Tomas M., Napolitano C., De G.L., et al. Polymorphisms in the NOS1AP gene modulate QT interval duration and risk of arrhythmias in the long QT syndrome. J Am Coll Cardiol 2010, 55:2745-2752.
72. Crotti L., Monti M.C., Insolia R., et al. Nos1ap is a genetic modifier of the long-QT syndrome. Circulation 2009, 120:1657-1663.
73. Manolio T.A., Collins F.S., Cox N.J., et al. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
74. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New Engl J Med 2006, 354:1264-1272.
75. Cohen J., Pertsemlidis A., Kotowski I.K., Graham R., Garcia C.K., Hobbs H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005, 37:161-165.
76. McKenney J.M., Koren M.J., Kereiakes D.J., Hanotin C., Ferrand A.-C., Stein E.A. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012, 59:2344-2353.
77. Stein E.A., Mellis S., Yancopoulos G.D., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012, 366:1108-1118.
78. Ramirez A.H., Shaffer C.M., Delaney J.T., et al. Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics 2012, [Epub ahead of print].
79. Damani S.B., Topol E.J. The case for routine genotyping in dual-antiplatelet therapy. J Am Coll Cardiol 2010, 56:109-111.
80. Roberts J.D., Wells G.A., Le May M.R., et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (rapid gene): a prospective, randomised, proof-of-concept trial. Lancet 2012, 379:1705-1711.
81. Gurbel P.A., Tantry U.S., Shuldiner A.R., Kereiakes D.J. Genotyping one piece of the puzzle to personalize antiplatelet therapy. J Am Coll Cardiol 2010, 56:112-116.
82. Ginsburg G.S., Burke T.W., Febbo P. Centralized biorepositories for genetic and genomic research. JAMA 2008, 299:1359-1361.
83. Green E.D., Guyer M.S. Charting a course for genomic medicine from base pairs to bedside. Nature 2011, 470:204-213.
84. Pulley J.M., Denny J.C., Peterson J.F., et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther 2012, 92:87-95.
85. McCarty C.A., Chisholm R.L., Chute C.G., et al. The eMERGE network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics 2011, 4:13.